Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study

[1]  J. Shah,et al.  CTNI-18. FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (rGBM) , 2020 .

[2]  R. Hájek,et al.  Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. , 2020, Blood reviews.

[3]  I. Vergote,et al.  Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. , 2019, Gynecologic oncology.

[4]  D. Boulware,et al.  A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer , 2019, The oncologist.

[5]  Margaret S. Lee,et al.  Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents , 2018, Oncotarget.

[6]  K. Camphausen,et al.  The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo , 2018, Molecular Cancer Therapeutics.

[7]  F. Meric-Bernstam,et al.  Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer , 2017, Breast Cancer Research.

[8]  R. Carlson,et al.  First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Carlson,et al.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Cusack,et al.  XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer , 2015, Clinical Cancer Research.

[11]  R. Garzon,et al.  Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. , 2015, Blood.

[12]  A. Sood,et al.  XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A , 2015, Clinical Cancer Research.

[13]  G. Pond,et al.  Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer , 2014, BJU international.

[14]  Kaushal Parikh,et al.  Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents , 2014, Journal of Hematology & Oncology.

[15]  E. Baloglu,et al.  Clinical translation of nuclear export inhibitors in cancer. , 2014, Seminars in cancer biology.

[16]  Yuh Min Chook,et al.  Atomic basis of CRM1-cargo recognition, release and inhibition. , 2014, Seminars in cancer biology.

[17]  N. Grishin,et al.  NESdb: a database of NES-containing CRM1 cargoes , 2012, Molecular biology of the cell.

[18]  D. Sullivan,et al.  Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.

[19]  M. Oren,et al.  Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. , 2012, Molecular cell.

[20]  V. Leaner,et al.  The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. , 2011, Biochimica et biophysica acta.

[21]  A. D. Van den Abbeele,et al.  Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. , 2010, AJR. American journal of roentgenology.

[22]  Li-wei Wang,et al.  Prognostic value of CRM1 in pancreas cancer. , 2009, Clinical and investigative medicine. Medecine clinique et experimentale.

[23]  Li-wei Wang,et al.  Prognostic value of CRM1in pancreas cancer , 2009 .

[24]  Chun Cheng,et al.  EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS , 2009, Neurosurgery.

[25]  Carsten Denkert,et al.  Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer , 2008, Cancer.

[26]  Minoru Yoshida,et al.  CRM1 is responsible for intracellular transport mediated by the nuclear export signal , 1997, Nature.

[27]  M. P. Holloway,et al.  The CRM1 nuclear export protein in normal development and disease. , 2012, International journal of biochemistry and molecular biology.

[28]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[29]  Y. Dong,et al.  The expression of CRM1 is associated with prognosis in human osteosarcoma. , 2009, Oncology reports.